Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8) an open-label randomised controlled phase 3 trial /

Soria Jean-Charles, Felip Enriqueta, Cobo Manuel, Lu Shun, Syrigos Konstantinos, Lee Ki Hyeong, Goeker Erdem, Georgoulias Vassilis, Li Wei, Isla Dolores, Guclu Salih Z, Morabito Alessandro, Min Young J, Ardizzoni Andrea, Gadgeel Shirish M, Wang Bushi, Chand Vikram K, Goss Glenwood D, Kollaborációs szervezet: LUX-Lung 8 Investigators, Somfay Attila, et al
2015

Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer

Wu Yi-Long, Tsuboi Masahiro, He Jie, John Thomas, Grohe Christian, Majem Margarita, Goldman Jonathan W., Laktionov Konstantin, Kim Sang-We, Kato Terufumi, Vu Huu-Vinh, Lu Shun, Lee Kye-Young, Akewanlop Charuwan, Yu Chong-Jen, de Marinis Filippo, Bonanno Laura, Domine Manuel, Shepherd Frances A., Zeng Lingmin, Hodge Rachel, Atasoy Ajlan, Rukazenkov Yuri, Herbst Roy S., Kollaborációs szervezet: ADAURA Investigators, Somfay Attila, et al
2020